H. Lundbeck A/s Class A · OMXCOP:HLUN_A
H. Lundbeck A/s Class A — Q1 2009 Earnings Presentation
76 slides from H. Lundbeck A/s Class A's earnings presentation, Jul 12, 2009
Slide 1: Investor presentation (Q1 2009)
H. LUNDBECK A/S Investor presentation (Q1 2009)
Slide 2: Safe Harbour Statement
Safe Harbour Statement This presentation contains forward-looking statements that provide our expectations or forecasts of future events such as new product introductions, product approvals and financial performance. Such forward-looking statements are subject to risks, uncertainties and inaccurate
Slide 3: Agenda
Agenda Lundbeck overview Projects in development Marketed products Financial figures 3
Slide 4: Update on recent events
Update on recent events Strategic Integration of US based Ovation Pharmaceuticals, Inc develops according to plan “Decisions Now” process ongoing Financials Guidance now includes Lundbeck Inc. Continued solid growth in Lundbeck’s key products and regions Strong uptake of Xenazine* Pipeline
Slide 5: Engines of growth
Engines of growth Decisions Now Lundbeck Inc. Pipeline • Products - achieving full • Integration on track Regulatory: potential of marketed • Sabril® • Positive initial uptake of • Serdolect® pharmaceuticals Xenazine* • Pipeline - maximising the • ATryn launch Phase III: value of new and innovative
Slide 6: Lundbeck's aspiration to be a high-growth, research based, CNS company
It's Lundbeck’s aspiration to be a high-growth, research based, CNS company Leverage on CNS capabilities to develop novel compounds to Successful product address unmet medical launches needs Implement strategy to - Lu AA21004 (mood Potential launch of: maximize shareholder disorders) value in 2011-1
Slide 7: Lundbeck – a fully integrated company focusing on CNS
Lundbeck – a fully integrated company focusing on CNS Lundbeck’s therapeutic areas (growth 2007 in %) USDm 25,000 ) %4 ) % (1 4 Global is (- s ho n pharmaceutical io yc ss Ps market 2007 re ep 20,000 D CNS, largest therapeutic area, ) 7% 17% of total pharmaceutical (1 Not within CNS y ps market il
Slide 8: Indications costly to society with high unmet medical needs
Lundbeck is involved in indications costly to society and with high unmet medical needs Rank* Disease Cipralex® / Lexapro® Launched 1 Cancer Lu AA21004 Clinical phase III 2 Unipolar depressive disorder and anxiety Lu AA24530 Clinical phase II Lu AA34893 Clinical phase II 3 Ischaemic heart disease 4
Slide 9: Agenda
Agenda Lundbeck overview Projects in development Marketed products Financial figures 9
Slide 10: Depression and anxiety – efficacy and onset of action needs improvement
Depression and anxiety – efficacy and onset of action needs improvement Treatment for non-responders - only some 50-60% of patients respond to therapy 150m people suffer from depression globally Importance (higher for escitalopram) according to WHO The world-market for anti-depressants is a Drug
Slide 11: The portfolio within mood disorders
The portfolio within mood disorders – markedly different to any marketed antidepressants Portfolio of three innovative novel compounds Clinical programme on Lu AA21004: Clinical phase II concluded in Autumn 2007: Lu AA21004 6 weeks treatment Lu AA24530 426 patients Lu AA34893 Two doses: 5 an
Slide 12: Lu AA21004 – receptor profil
Lu AA21004 – receptor profil SSRI Lu AA21004 offers Pharmacological profile different from current 5-HTT antidepressants Serotonin Increases multiple neuro-transmitters Occupancy rate: 80% 5-HT3 antagonist, 5-HT1A agonist and 5-HT enhancer Increases 5-HT levels at low 5-HT transporter occupa
Slide 13: Psychosis – still substantial unmet medical needs in therapy
Psychosis – still substantial unmet medical needs in therapy The global market for anti-psychotics Improved treatment of constitutes USD 21bn Importance cognitive dysfunction In 2007 the US market grew by 12% Improved treatment of The European market grew by 9% Negative symptoms 50-60% of to
Slide 14: The burden of schizophrenia is large and multifaceted
The burden of schizophrenia is large and multifaceted Brain disorders account for 35% of total socio-economic cost of diseases in Europe Schizophrenia is heavily stigmatized = Yearly cost (EURbn) Prevalence (mio.) create a vicious cycle of discrimination 120 45 40 Prevalence 100 Costs 35 Social
Slide 15: Lundbeck's psychosis portfolio
Lundbeck’s psychosis portfolio Lundbeck’s portfolio addresses the Sertindole (US) patho-physiology with mono and add-on therapies Bifeprunox Lu AE58054 The different symptom domains may have a different patho-physiology Lu 31-130 One compound for all symptoms Lu AA39959 may not be realistic 0
Slide 16: Serdolect has market potential in the US
Serdolect® has market potential in the US NDA submitted in September 2008 FDA feedback expected in May 2009 Cognitive The US anti-psychotics market is Negative function valued at USD 12.6bn per year symptoms Annual growth of around 12% g t i o nin c Extensive switch opportunities1) Fu n No
Slide 17: Serdolect outcome at the PDAC meeting
Serdolect® outcome at the PDAC meeting Serdolect® evaluated by an FDA PDAC on 7 April 2009 The committee reviewed comprehensive Broadly efficacious against positive and data from clinical trials including the SCoP negative symptoms Study Low rate of suicide The PDAC voted that Improves c
Slide 18: The Sertindole Cohort Prospective (SCoP) study
The Sertindole Cohort Prospective (SCoP) study Overall safety conclusion Overall study design No difference in all-cause mortality between Sertindole (n = 4,905) Serdolect® and risperidone Very few cases of arrhythmia Randomization All confounded by medical history or concomitant Risperidone (
Slide 19: Bifeprunox – additional clinical phase III trials initiated
Bifeprunox – additional clinical phase III trials initiated Bifeprunox is a partial dopamine D2 and 5-HT1A receptor agonist Bifeprunox target population IP 2017 + possible extensions Clinical trial design Severity of schizophrenia symptoms Two clinical phase III trials; each enrolling 450 Non-
Slide 20: Lu 31-130 – pharmacological profile and expected clinical profile
Lu 31-130 – pharmacological profile and expected clinical profile Lu 31-130 Two Phase II studies ongoing: Lu 31-130 has a multi-receptorial Clinical trial programme 1 profile A phase II, placebo controlled, dose- Affinity to monoaminergic escalation study in 210 patients with receptors schizophr
Slide 21: Lu AE58054 – pharmacological profile in animal models
Lu AE58054 – pharmacological profile in animal models Lu AE58054 has been investigated in healthy volunteers and patients with schizophrenia Is generally well tolerated and has a Lu AE58054 Lu AE58054 is a selective 5-HT6 benign side-effect profile antagonist Initiation and conduct of clinical
Slide 22: Bipolar disorder – still substantial unmet medical needs
Bipolar disorder (BPD) – still substantial unmet medical needs in therapy The prevalence is estimated around 1% Mono-therapies that treat depression Bipolar disorder (or manic-depressive illness is Importance and manic stage a chronic and debilitating psychiatric illness Improved maintenance the
Slide 23: Lu AA39959 – a new class of compounds targeting bipolar disorder
Lu AA39959 – a new class of compounds targeting bipolar disorder Lu AA39959 is expected to show clear and Lu AA39959 convincing effects in patients with bipolar disorder, Lu AA39959 has a unique target likely associated with profile: first in class Modulator of selected Benign safety/tolerabilit
Slide 24: Stroke – still substantial unmet medical needs in therapy
Stroke – still substantial unmet medical needs in therapy Unmet medical need: Thrombolytics with a longer Acute Ischemic stroke (AIS) accounts for 67-85% of all Importance treatment window strokes AIS is a leading cause of death in the major pharmaceutical markets and the leading cause of severe
Slide 25: Desmoteplase (ph III) – a possible improvement of existing stroke therapy
Desmoteplase (ph III) – a possible improvement of existing stroke therapy Responder rates DIAS/DEDAS DIAS-2 (pooled) Desmoteplase Nine hour time window increases 50% addressable market 40% Potential to decrease bleeding complications 30% Potential to improve neurological outcome 20% Post-hoc
Slide 26: Alcohol misuse – still substantial unmet medical needs in therapy
Alcohol misuse – still substantial unmet medical needs in therapy Unmet medical need: Greater resources - the number of treatment Alcohol exerts an influence on the glutamine, gamma- Importance facilities and trained physicians is inadequate aminobutyric acid (GABA) dopamine, and endogenous opioid
Slide 27: Nalmefene (ph III) – a potential new treatment paradigm
Nalmefene (ph III) – a potential new treatment paradigm Nalmefene Clinical phase III study ongoing: In clinical trials nalmefene reduces Consists of three studies with a total of Heavy Drinking Days ~1,800 patients Total consumption Two placebo-controlled 24-week Nalmefene can leverage o
Slide 28: Epilepsy – still substantial unmet medical needs in therapy
Epilepsy – still substantial unmet medical needs in therapy Prevalence of epilepsy: 1% to 2% of population New and better treatment for 30% live with seizures uncontrolled by existing Importance refractory seizures therapies More choices of drugs, especially with different mechanisms of Curren
Slide 29: Sabril (vigabatrin) in refractory complex partial seizures
Sabril® (vigabatrin) in refractory complex partial seizures (rCPS) Clinically meaningful improvements noted Complete seizure freedom (7-12%) Significant reductions in seizure frequency (> 50% Sabril® * and > 75% criteria) Unique MoA as a selective and irreversible inhibitor of GABA- Safety pro
Slide 30: Sabril (vigabatrin) in infantile spasms (IS)
Sabril® (vigabatrin) in infantile spasms (IS) Infantile spasms (IS) / West syndrome: Sabril® * Serious and catastrophic disease with unmet Unique MoA as a selective and irreversible medical need inhibitor of GABA-transaminase Seizures start early in life, most often in first year Unanimous Advis
Slide 31: Clobazam and I.V. carbamazepine - overview
Clobazam and I.V. carbamazepine - overview Clobazam Intravenous carbamazepine Clobazam is a GABA enhancer Niche product used in hospital Efficacy in Lennox-Gastaut Syndrome channels for patients taking oral (LGS) demonstrated in phase II carbamazepine, but need Generally well tolerated with mo
Slide 32: Lundbeck's development pipeline
Lundbeck’s development pipeline Compound NDA Activity Phase I Phase II Phase III Indication Filing Sabril® Refractory complex partial seizures/ Infantile spasms GABA transaminase inhibitor * Serdolect® - US Dopamine/serotonin ** Schizophrenia Lu AA21004 5-HT3 antagonist, 5-HT1A agonist 2010 Depressi
Slide 33: Agenda
Agenda Lundbeck overview Projects in development Marketed products Financial figures 33
Slide 34: Cipralex/Lexapro (escitalopram) - top of the class anti-depressant
Cipralex®/Lexapro® (escitalopram) - top of the class anti-depressiv Cipralex® is an ASRI* with a unique mode of action, Serotonin Dual-action Estimated to have treated more than 160 million patients since launch Has demonstrated superior efficacy in the treatment of depression and anxiety in n
Slide 35: Cipralex – strong growth in Europe and International Markets
Cipralex® (escitalopram) – strong growth in Europe and International Markets Anti-depressant marked Market growth, volume Europe Market share, value Cipralex® sales in Europe for the quarter was DKK 913m 12% 17.9% 20% (+11%) 18% 10% 16% Cipralex® still the most subscribed branded anti- 8% 14% de
Slide 36: Lexapro – now approved for the treatment of adolescents
Lexapro® (escitalopram) – now approved for the treatment of adolescents Anti-depressant market US US revenue of DKK 626m in Q1 2009, down 5% Market growth, Market share, volume value compared to 2008 9% 24.6% 30% Lexapro® is the most prescribed branded 25% 7% antidepressant in the US 20% 5% Ma
Slide 37: Ebixa (memantine) – efficacious even in severe Alzheimer's disease
Ebixa® (memantine) – efficacious even in severe Alzheimer’s disease Ebixa® is the only NMDA* receptor antagonist approved for the treatment of Alzheimer’s disease A very efficacious, well-tolerated and safe treatment with placebo-like side effects Only therapy licensed for the treatment of mod
Slide 38: Ebixa – growth driven by underlying market development
Ebixa® (memantine) – growth driven by underlying market development Anti-Alzheimer’s market Market growth, volume Europe Market share, value Ebixa® revenue in Europe of DKK 431m (+15%) 20% 16.1% 18% European market share is stable around 16% in 16% 15% a high growth market 12% 12% Continued ro
Slide 39: Azilect (rasagiline) – only treatment proven to slow Parkinson's progression
Azilect® (rasagiline) – only treatment of Parkinson’s disease proven to slow disease progression A potent, selective, irreversible monoamine oxidase (MAO) type-B inhibitor Approved for monotherapy and adjunct therapy with levodopa treatment Azilect® is a well tolerated therapy for early and ad
Slide 40: Azilect – strong growth across all markets
Azilect® (rasagiline) – strong growth across all markets Anti-Parkinson’s market Market growth, Europe Market share, Azilect® sales rose to DKK 78m in Q1 2009, up volume 6% value 7.1% 8% 43% compared to 2008 5% 7% European sales at DKK 70m (+42%), Int. 6% 4% 5% Markets sales at DKK 7m (+53%) 3%
Slide 41: Xenazine (tetrabenazine) – promising initial launch
Xenazine* (tetrabenazine) – promising initial launch Selectively inhibiting vesicular monoamine transporter enzyme (VMAT)-2, thereby depleting pre-synaptic dopamine Approved for chorea associated with Huntington’s disease Only drug approved by FDA specifically for any symptom of HD Addresses
Slide 42: Very strong initial uptake for Xenazine
Very strong initial uptake for Xenazine* Volume (standard Rx) 350 Launched in the US by the end of 300 November 2008 250 Xenazine* has been very well received 200 More than 1,300 patients initiated 150 Xenazine* treatment by the end of 100 Q1 2009 Level for renewals higher than 50 expected 0
Slide 43: ATryn (recombinant anti-thrombin alpha) - overview
ATryn® (recombinant anti-thrombin alpha) - overview Hereditary Anti-thrombin Deficiency (HAD) ® ATryn A potentially life-threatening rare disease Treatment of patients with with limited therapeutic alternatives Hereditary Anti-thrombin Deficiency (HAD) to prevent People with HAD are at increas
Slide 44: Agenda
Agenda Lundbeck overview Projects in development Marketed products Financial figures 44
Slide 45: Financial figures – distribution of revenue in Q1 2009
Financial figures – distribution of revenue in Q1 2009 DKKm DKKm 10% Q1 2007 Q1 2008 Q1 2009 1,800 12% 14% 15% Growth DKK 1,600 Growth LC 1,400 Lundbeck’s revenue excl. the divestment 1,200 of LifeCycle Pharma (LCP) grew 8% in Q1 1,000 5% 4% 18% 9% 13% 2009 1,675 6% 7% 24% 800 1,516 1,334 600 400
Slide 46: Financial figures – distribution of costs in Q1 2009
Financial figures – distribution of costs in Q1 2009 Costs in % of total revenue and total costs (excl. one-offs) DKKm 2,500 COS SG&A R&D 2,279 2,000 1,924 1,957 1,781 23% 1,581 18% 18% 1,500 20% 16% 1,000 35% R&D costs for Q1 2009 up 37% 41% 37% 33% 36% compared to 2008, corresponding to 500 23%
Slide 47: Key deliverables the next 12 months
Key deliverables the next 12 months Existing products FDA decision on Serdolect® in the US for schizophrenia (PDUFA date 15 May 2009) Continue the roll-out of ATryn® in the US for hereditary anti-thrombin deficiency Further enhance Xenazine’s market penetration Product launches Potential lau
Slide 48: Lundbeck Inc. impact on P&L for 2009
Lundbeck Inc. impact on P&L for 2009 (DKK) Revenue EBIT Profit Lundbeck Inc. is before tax expected to generate approx DKK 1.1bn in Lundbeck Inc. ~ 1.1bn ~ 150mn ~ 150mn revenue Acquisition accounting -- ~ (183)mn ~ (183)mn Lundbeck Inc. has neutral net effect on EBIT excluding Additional amorti
Slide 49: Financial guidance
Financial guidance 2008 2009* 2009* Previous guidance New guidance New guidance (DKKm) (DKKbn) (DKKbn) Unchanged Revenues 11,282 12-12.5 13.1-13.6 expectations for Lundbeck excl. Lundbeck Inc. EBITDA 3,417 -- 3.5-3.7 Significant contribution from Lundbeck Inc. EBIT 2,354 3-3.2 2.8-3.0 sales EB
Slide 50: Balance sheet and cash position
Balance sheet and cash position (DKKm) 31.12.2008 31.03.2009 Intangible assets 2,016 7,552 Other non-current assets 3,370 3,380 Intangible assets Current assets 7,140 5,068 related to the acquisition amounts to Assets 12,526 16,000 DKK 5.8bn DKK 3.5bn of the Equity 7,511 8,115 transaction has be
Slide 51: Multiple strategies to drive long-term growth
Multiple strategies to drive long-term growth Our path forward… Streamline current business Explore opportunities on Lundbeck’s strengths commercial products • A specialist in Market potential psychiatry and pioneer Delivering on our late-stage in neurology • Large market portfolio, but… oppor
Slide 52: For more information please contact Investor Relations
For more information please contact Investor Relations Jacob Tolstrup Palle Holm Olesen Joan Loua Director; IR and Communication Head of Investor Relations Investor Relations coordinator Tel: +45 36 43 30 79 Tel: +45 36 43 24 26 Tel: +45 36 43 45 98 Fax: +45 36 43 82 62 Fax: +45 36 43 82 62 Fax: +45
Slide 53: Appendix
Appendix 53
Slide 54: Lundbeck share
Lundbeck share Share information: Trading code: Free float (approximately 60m Reuters (LUN.CO) / Bloomberg (LUN DC) shares) is traded 1.5+ time over ISIN Number DK0010287234 annually (daily trade of approximately Unsponsored ADR programmes 0.35m) HLUKY, CUSIP 40422M107 Index examples: End
Slide 55: Continued solid performance in all products
Continued solid performance in all products Cipralex® • Results from a a multiple-treatments meta-analysis comparing efficacy and acceptability of 2 new-generation Market share Y/Y antidepressants support Cipralex1) (Feb 2009) Change • “Decisions Now” Cipralex® • Venlafaxine patent expiration - Euro
Slide 56: Revenue – by product / by region (quarterly)
Revenue – by product / by region (quarterly) International Total Europe USA Markets Q1 Q1 Q1 Q1 Q1 Q1 Q1 Q1 DKKm 2009 2008 2009 2008 2009 2008 2009 2008 Total revenue 3,226 2,882 1,675 1,516 687 661 708 651 Growth 12% 10% 4% 9% Cipralex® 1,363 1,216 913 823 - - 450 393 Growth 12% 11% - 15% Lexapro®
Slide 57: Revenue – by product / by region (yearly)
Revenue – by product / by region (yearly) International Total Europe USA Markets DKKm 2008 2007 2008 2007 2008 2007 2008 2007 Total revenue 11,282 10,985 6,213 5,501 2,464 2,599 2,409 2,194 Growth 3% 13% -5% 10% Cipralex® 4,829 4,094 3,355 2,827 - - 1,474 1,267 Growth 18% 19% 16% Lexapro® 2,464 2,59
Slide 58: Revenue, quarterly figures
Revenue, quarterly figures Revenue, DKK million Growth, Y/Y, % Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 2008 2008 2008 2009 2008 2008 2008 2009 Total revenue 2,938 2,810 2,653 3,226 12% (5%) (6%) 12% Cipralex® 1,234 1,228 1,151 1,363 20% 17% 12% 12% Lexapro® 692 602 509 626 8% (14%) (19%) (5%) Ebixa® 467 480 475 526
Slide 59: Revenue, yearly figures
Revenue, yearly figures Revenue, DKK million Growth, Y/Y, % 2004 2005 2006 2007 2008 2005 2006 2007 2008 Total revenue 9,733 9,070 9,221 10,985 11,282 -7% 2% 19% 3% Cipralex® 1,661 2,625 3,508 4,094 4,829 58% 34% 17% 18% Lexapro® 2,420 2,552 1,923 2,594 2,464 5% -25% 35% -5% Ebixa® 722 1,105 1,361 1
Slide 60: Costs, quarterly figures
Costs, quarterly figures DKK million Growth, Y/Y, % Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 2008 2008 2008 2009 2008 2008 2008 2009 Revenue 2,938 2,810 2,653 3,226 12% (5%) (6%) 12% Production costs 468 433 460 487 18% (5%) (46%) 2% Distribution costs 632 571 689 673 7% (2%) 5% 19% Administrative expenses 427 385 4
Slide 61: Costs, yearly figures
Costs, yearly figures DKK million Growth, Y/Y, % 2004 2005 2006 2007 2008 2005 2006 2007 2008 Revenue 9,733 9,070 9,221 10,985 11,282 -7% 2% 19% 3% Production costs 1,725 1,488 1,646 2,198 1,837 -14% 11% 34% -16% Distribution costs 2,302 2,337 2,419 2,409 2,459 2% 4% 0% 2% Administrative exp. 1,364
Slide 62: Average US$ hedging rates for 2009
Average US$ hedging rates of USD/DKK 5.36 (cash) and USD/DKK 5.13 (reporting) for 2009 Actual rates (USD/DKK) Forward rates (USD/DKK) 7 6.5 6 5.75 5.83 5.63 5.51 5.5 5.36 5.31 5.16 4.96 4.96 4.99 5 4.99 4.5 Quarterly figures 4 '07 '08 '09 Q1 Q2 Q3 Q4 '09 '09 '09 '09 Average USD exchange rate Average
Slide 63: Ovation (now Lundbeck, Inc.) overview
Ovation (now Lundbeck, inc.) overview Company was founded by Jeffrey Aronin and started commercial operations in 2002 Headquartered in Deerfield, IL Approximately 300 employees Professional interaction with Key Opinion Leaders, patient organisations and FDA Strong track record in developme
Slide 64: Solid historic performance in Ovation
Solid historic performance in Ovation – Brain disorders to be key future revenue driver Revenue distribution (2008) Ovation - historic performance USDm 2005 2006 2007 2008 21% Net sales 60.1 142.7 176.1 204.0 Growth % 55% 137% 23% 16% Gross profit 44.9 117.1 139.5 160.4 Gross margin 75% 82% 79% 79%
Slide 65: Global IP position
Global IP position Europe Bifeprunox: Compound patent in majority of countries to Feb. 2017 (excl. extension) Escitalopram: Compound patent in majority of countries to May-June 2014. Process patent in majority of countries to June 2014 Memantine: Data exclusivity until 2012; use patent until 2014 (i
Slide 66: Bifeprunox is expected to improve schizophrenia symptoms over the long-term
Bifeprunox is expected to improve schizophrenia symptoms over the long-term Symptoms were stable over 6 months on bifeprunox In clinical trials bifeprunox has shown: treatment in a time-to-deterioration trial Anti-psychotic effect (acute+chronic) In chronic, stabilised schizophrenia, bifeprunox
Slide 67: Worldwide pharmaceutical market 2007
Worldwide pharmaceutical market 2007 – USD 671.7 billion (+10%) 8% (+13%) 17% (+10%) 3% (+11%) 5% (+10%) (N) CNS (C) Cardiovascular 5% (+11%) (A) Alimentary (J) Anti-Infectives 15% (+2%) 6% (+5%) (L) A+Immun (R) Respiratory (B) Blood 8% (+13%) (M) Muscolo-Skeletal (G) G.U.& Sex Hormones (D) Dermatol
Slide 68: Worldwide CNS market 2007
Worldwide CNS market 2007 – USD 111.8 billion (+10%) 11% (+22%) 19% (+14%) 2% (+6%) N5A Antipsychotics 2% (+3%) N6A Antidepressants 3% (+8%) N3A Anti-Epileptics N2B Non-Narcotic Analgesics 3% (+19%) N2A Narcotic Analgesics 4% (-8%) N7D Anti-Alzheimers 18% (-4%) N5B Hypnotics & Sedatives 5% (+21%) N4
Slide 69: Alcohol (N7E-2007)
Alcohol (N7E-2007) – USD 172 million (+22%) International markets 11% (14%) North America 36% (+46%) Europe 53% (+12%) Leading product Marketing Corporation Sales 2007 (USDm) Growth in % Campral® Merck 74 11 Antabuse® Barr/Sanofi-Aventis 26 48 Nemexin® BMS/Cephalon 11 7 Vivitrol® BMS/Cephalon 11 479
Slide 70: Anti-Alzheimer's (N7D-2007)
Anti-Alzheimer’s (N7D-2007) – USD 5.6 billion (+21%) International markets Value Market Shares of N7D 16% (+29%) Europe M12 2007 USA M12 2007 Rivastigmine Memantine Europe 30% (+22%) North Galantamine America 54% (+19%) Donepezil 0% 10% 20% 30% 40% 50% 60% Source: IMS Health, May 2008, retail only L
Slide 71: Anti-depressants (N6A-2007)
Anti-depressants (N6A-2007) – USD 19.8 billion (- 4%) International Value Market shares of N6A markets 13% (+15%) VENLAFAXINE SERTRALINE PAROXETINE FLUOXETINE Europe M12 2007 North America USA M12 2007 Europe 62% (-12%) ESCITALOPRAM 25% (+9%) DULOXETINE CITALOPRAM BUPROPION 0% 5% 10% 15% 20% 25% 30%
Slide 72: Anti-epileptics (N3A - 2007)
Anti-epileptics (N3A - 2007) – USD 15.3 billion (+17%) PLEASE NOTE: Ovation acquisition subject to approval by FTC International markets 11% (+18%) Europe North America 22% (+21%) 67% (+15%) Leading product Marketing Corporation Sales 2007 (USDm) Growth in % Topamax® J&J 2496 17 Lamictal® GlaxoSmith
Slide 73: Anti-Parkinson's (N4A - 2007)
Anti-Parkinson’s (N4A - 2007) – USD 3.7 billion (+19%) Value Market Shares of N4A - Europe International North Europe M12 2007 markets America Stalevo® 21% (+8%) 36% (+23%) NMDA ANTAGONISTS MAOI LEVODOPA DERIVATE DOPAMINE AGONISTS COMT INHIBITORS ANTICHOLINERGICS 0.00% 10.00% 20.00% 30.00% 40.00% 50
Slide 74: Anti-psychotics (N5A-2007)
Anti-psychotics (N5A-2007) – USD 20.8 billion (+14%) International Value Market Shares of N5A Europe M12 2007 markets ZIPRASIDONE USA M12 2007 11% (+17%) RISPERIDONE QUETIAPINE OLANZAPINE North America CLOZAPINE Europe 64% (+12%) 26% (+19%) ARIPIPRAZOLE AMISULPRIDE 0% 5% 10% 15% 20% 25% 30% 35% Sour
Slide 75: Hypnotics (N5B-2007)
Hypnotics (N5B-2007) – USD 5.0 billion (- 8%) Value Market Shares of N5B International Europe Q4 2007 markets Ezopiclone USA Q4 2007 17% (+4%) Zaleplon Zopiclone Europe North 22% (+10%) America Zolpidem 61% (-16%) 0% 10% 20% 30% 40% 50% 60% 70% 80% Source: IMS Health, May 2008, retail Leading produc
Slide 76: Stroke, Fibrinolytics (B1D-2007)
Stroke, Fibrinolytics (B1D-2007) – USD 743 million (+10%) International markets 19% (+14%) North America 49% (+6%) Europe 32% (+13%) Leading product Marketing Corporation Sales 2007 (USDm) Growth in % Activase®/Actilyse® Roche/Boehringer 365 20 Metalyse®/Tnkase Roche/Boehringer 166 (1) Retavase®/Rap